Pricing the first biopharma IPO in the month of September, precision medicine company Electra Therapeutics Inc. is raising $350 million to advance the phase II/III registrational development of novel pan-SIRP monoclonal antibody (mAb) ipsoprubart in secondary hemophagocytic lymphohistiocytosis (sHLH) toward a BLA filing.